<DOC>
	<DOCNO>NCT00999869</DOCNO>
	<brief_summary>Alopecia areata one common cause non-scarring alopecia . The pathogenesis still unclear , however , believe autoimmune disease . This disease life-threatening condition significant psychological impact patient 's quality life . Many trigger propose viral infection , stress neurologic factor . There many study show correlation disease activity neurotransmitter level . Substance P calcitonin gene-related peptide play major role early stage disease . These substance cause imbalance CD4/CD8 lymphocyte pathologic site loss immune privilege hair follicle . The conventional treatment alopecia areata intralesional corticosteroid injection might treat end pathogenesis process . There therapeutic intervention origin disease . Fortunately , botulinum toxin A could novel treatment alopecia areata . The botulinum toxin A demonstrate inhibition release substance P many publication . To sum , treatment alopecia areata intralesional corticosteroid injection still standard treatment , nevertheless , patient receive treatment every month regrowth scalp hair . Corticosteroid injection several side effect , example , skin atrophy , pigmentary change hypothalamic-pituitary-adrenal axis suppression . Moreover , injection pain also affect psychological aspect . This study purpose evaluate efficacy botulinum toxin A alopecia areata reduce corticosteroid side effect , well , others opportunity cost . There prospective , randomized-controlled trial comparison study botulinum toxin A injection corticosteroid injection alopecia areata , therefore , investigator conduct study great benefit alopecia areata patient future research disease etiology .</brief_summary>
	<brief_title>The Comparison Study Intralesional Botulinum Toxin A Corticosteroid Injection Alopecia Areata</brief_title>
	<detailed_description>Inclusion criterion 1 . Patients must 18 year old 2 . Newly diagnose multiple alopecia areata 3 . Patient lesion side scalp . 4 . Lesions 's diameter vary 2-6 cm Exclusion criterion 1 . Having active scalp inflammation 2 . Allergic botulinum toxin A human albumin 3 . Receiving medication interfere efficacy botulinum toxin macrolides antimicrobial agent neuromuscular medication 4 . Diagnosed neuromuscular disease Myasthenia gravis 5 . Pregnant , breast feeding , plan pregnant patient</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Inclusion criterion Patients must 18 year old Newly diagnose multiple alopecia areata Patient lesion side scalp . Lesions 's diameter vary 26 cm Exclusion criterion Having active scalp inflammation Allergic botulinum toxin A human albumin Receiving medication interfere efficacy botulinum toxin macrolides antimicrobial agent neuromuscular medication Diagnosed neuromuscular disease Myasthenia gravis Pregnant , breast feeding , plan pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Newly diagnose</keyword>
	<keyword>Alopecia areata</keyword>
	<keyword>Botulinum toxin A</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Intralesional injection</keyword>
</DOC>